According to John Campbell, Ph.D., who reported on his YouTube show, the UK has committed $1 billion to the development of Moderna mRNA flu vaccine, despite the fact that the vaccine is still in very early clinical trials.
Must Watch: Would you live on 3D Printed Mars for a year for $60,000?
The National Institutes of Health is running a Phase 1 clinical trial on an experimental mRNA universal influenza vaccine developed by researchers at the National Institute of Allergy and Infectious Diseases’ (NIAID) Vaccine Research Center.
Although the vaccine is only in very early clinical trials, the U.K. government already has committed to a £1 billion deal with Moderna to buy the mRNA vaccines for flu and other respiratory viruses over the next 10 years, John Campbell, Ph.D., reported on his YouTube show.
“This really is quite bizarre in my view,” said Campbell, a retired nurse teacher in England who hosts a popular YouTube show that explains evolving science on COVID-19 and related issues.
“Why don’t we get the trial data first and then think about giving the thousand million pounds [£1 billion]” for the mass manufacture of the vaccines, he asked.
Subscribe to GreatGameIndia
Campbell explained the clinical trial details. The claim, he said, is that the vaccine is “universal” and so will work against all flu variants — unlike existing flu vaccines that are adjusted each year depending on which flu variant is dominant.
The study will enroll 50 volunteers ages 18 through 49 at the Duke Human Vaccine Institute in Durham, North Carolina, to test an mRNA lipid nanoparticle vaccine (H1ssF-3928 mRNA-LNP) for safety and for its capacity to induce an immune response.
“They are claiming, the National Institutes of Health in the United States are claiming
that by testing 50 healthy volunteers 18 through to 49 they can assess the safety of this vaccine. This is a parody of research in my view,” Campbell said.
Three groups of 10 participants each will receive doses of 10, 25 and 50 micrograms of lipid nanoparticles containing the mRNA to make the influenza antigen.
Campbell raised two issues with the research. First, he said, it is known from Australian studies that lipid nanoparticles are so small they can circulate throughout the body rather than staying at the injection site, as originally promised — this can be dangerous.
Second, he said, the amount of mRNA injected is not directly related to the amount of antigen produced.
Swedish researchers reported in a study published in the British Medical Journal that mRNA COVID-19 vaccines are linked to an increased risk of vaginal bleeding.